CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: WTDEC who wrote (384)	11/21/1999 2:49:00 AM
From: Bob L	Read Replies (1) of 666

Yep, I read the quote of Ende. I think he is correct when he suggests "investors not compare the drugs across independent studies as different traits of the patient populations within the studies may bias the results." Look how much variation in results there are among the abstracts of the same drugs. Look how much variation between phases of the same drug. We all suffer from investment-induced bias. I think it is important to keep that in mind. When we get peer-reviewed literature that concludes there a better efficacy-safety profile for bexxar, I will cheerfully concede the point and you all can say you told me so. As V1 says this is an excellent discussion. Thanks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next